Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 2590 of 6351
-
Desperate patients get early access to experimental brain drug
Disease control Expanded access (ended)This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Fosigotifator prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential …
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hope for mastocytosis patients: expanded access to bezuclastinib
Disease control Expanded accessThe purpose of this expanded access program (EAP) protocol is to provide investigational bezuclastinib to patients with a diagnosis of nonadvanced systemic mastocytosis (NonAdvSM) or advanced systemic mastocytosis (AdvSM) who have received and failed or been intolerant to at leas…
Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New imaging tool helps doctors see brain tumors more clearly
Diagnosis Expanded accessThe participants are being asked to get this PET scan because the participants have or may have cancer in the central nervous system (head, neck, or spine), and the investigator and the patient's physician thinks that this scan may provide useful information for the participant's…
Sponsor: St. Jude Children's Research Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rare metabolic disease patients: expanded access to triheptanoin
Disease control Expanded accessExpanded access may be provided for qualified patients who have limited treatment options and are not eligible for a clinical trial.
Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Second chance: yescarta offered to lymphoma patients despite manufacturing hiccups
Disease control Expanded accessThe goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.
Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope: expanded access to cemiplimab for cancer patients
Disease control ApprovedProvide expanded access of cemiplimab in patients with solid tumors
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Early access to promising cancer pill before official approval
Disease control Expanded accessThis is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential ben…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for rare blood and kidney diseases: iptacopan access program opens
Disease control Expanded accessThe purpose of this registration form is to list all Managed Access Programs (MAPs) related to LNP023, Iptacopan
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for kidney disease patients: managed access to EXV811, atrasentan
Disease control Expanded accessThe purpose of this registration is to list Managed Access Programs (MAPs) related to EXV811, Atrasentan
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug ABBV-706 made available for some lung cancer patients before approval
Disease control Expanded accessThis is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-706 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benef…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for leukemia patients allergic to key chemo drug
Disease control Expanded access (ended)The purpose of this study is to make Erwinase available to patients with acute lymphoblastic leukemia (ALL) who have had previous allergic reactions to certain formulations of L-asparaginase.
Sponsor: Phoenix Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New stem cell filter could make transplants safer for vulnerable patients
Disease control Expanded accessAllogeneic stem cell transplantation (alloSCT) is utilized for various underlying diseases. AlloSCT is limited by graft versus host disease (GVHD), graft rejection, viral infections, and post-transplant lymphoproliferative disorders. To mitigate graft versus host disease, graft m…
Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Early access program offers investigational meningioma treatment
Disease control Expanded accessThis Expanded Access Program (EAP) is intended to provide eligible participants with access to ITM-11 prior to approval by local regulatory authorities. Program availability is subject to country eligibility. The treating physician must determine, based on the individual patient´…
Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Lifeline for hunter syndrome patients: continued access to Brain-Targeting therapy
Disease control Expanded accessAs the HGT-HIT-046 (NCT01506141) and SHP609-302 (NCT02412787) studies are completed and closed, this post-trial access (PTA) program provides TAK-609 to participants in these studies for whom the benefit:risk ratio of continued treatment with idursulfase-IT remains positive.
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Last-Resort cancer vaccine made available for AML and MDS patients
Disease control Expanded accessSingle patient expanded access program to provide galinpepimut-S for eligible patients with AML or MDS who have no other treatment option.
Sponsor: Sellas Life Sciences Group • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental device aims to tame disease
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Experimental device aims to transform disease control
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a Two-Drug combo help teens with severe mental illness?
Disease control Expanded accessTo provide continued access to OLZ/SAM for pediatric participants with schizophrenia or bipolar I disorder who have completed participation in the ALKS 3831-A313 long-term safety extension study.
Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a new device change treatment?
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a new device change medical care?
Knowledge-focused Details not publishedSponsor: [Redacted] • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC